Diabetes (type 2) - glitazones (replaced by CG66)

Glitazones in the treatment of type 2 diabetes (Review of TA9 and TA21)

Summary

The recommendations in this technology appraisal have been replaced by recommendations in the type 2 diabetes clinical guideline published in May 2008. Therefore this guidance is obsolete.

Guidance documents

• No documents found

Implementing this guidance

• No documents found

• How this guidance was produced
• Background information

We will consult on our review plans for this guidance in July 2006